Health
Infant RSV shot faces final hurdle at CDC, could be available by fall
A RSV-infected child receives treatment, as RS-Virus infections spread among children at Missio children’s clinic Moenchberg, in Wuerzburg, Germany, December 2, 2022. Heiko Becker | Reuters Americans may soon have access to a shot that protects babies from respiratory syncytial virus, or RSV, the leading cause of hospitalization among infants in the U.S. A panel […]
Read More
Moderna shares rise on better Covid vaccine outlook despite sharp drop in sales
Artur Widak | Nurphoto | Getty Images Shares of Moderna rose Thursday after the biotech company hiked its full-year outlook for its Covid vaccine, its only marketable product, despite reporting a quarterly loss and sharp drop in revenue. Here are Moderna’s results: Loss per share: $3.62 (That may not be comparable to the $4.04 expected by […]
Read More
FDA warns some Tydemy birth control pills may not be effective, could result in unexpected pregnancy
Signage is seen outside the U.S. Food and Drug Administration headquarters in White Oak, Maryland, Aug. 29, 2020. Andrew Kelly | Reuters The U.S. Food and Drug Administration has warned that some Tydemy birth control pills may not be effective, several days after the manufacturer recalled two batches of the medication that were distributed in […]
Read More
Humana calms Wall Street’s jitters with quarterly results, clearing way for stock to run higher
Humana (HUM) reported second-quarter results Wednesday that were much better than feared, sending its stock price soaring and giving us the confidence to stick with the jilted health insurer. Revenue for the three months ended June 30 rose 13% year-over-year, to $26.75 billion, exceeding analysts’ estimates of $26.23 billion, according to Refinitiv. Adjusted earnings-per-share (EPS) […]
Read More
Humana shares rise after insurer says medical costs came in lower than expected
A Humana office in Louisville, Kentucky, July 31, 2023. Jon Cherry | Bloomberg | Getty Images Humana shares rose Wednesday after the health insurer said medical costs came in lower than expected during its second-quarter earnings report. The results ease investor concerns two months after Humana and rival UnitedHealth Group warned that a surge in […]
Read More
GSK sues Pfizer in U.S. court for patent infringement over RSV vaccine
Jun Li | Istock | Getty Images GlaxoSmithKline on Wednesday sued Pfizer in U.S. court, alleging patent infringement over Britain-based GSK’s respiratory syncytial virus vaccine. GSK claims Pfizer’s RSV vaccine, Abrysvo, infringes on four of its patents related to the antigen used in its own shot. related investing news “Upon information and belief, Pfizer knowingly […]
Read More
Walgreens is now offering RSV vaccines for older adults
Respiratory syncytial virus viral vaccine under research. Hailshadow | Istock | Getty Images Walgreens is now offering the respiratory syncytial virus vaccine for older adults nationwide, the pharmacy chain said on Tuesday. People ages 60 and older can schedule an appointment this week through Walgreens’ app, website, by phone or by visiting their local pharmacy. […]
Read More
Merck beats on revenue boosted by Keytruda sales, but posts quarterly loss due to Prometheus deal
Merck on Tuesday reported second-quarter revenue that topped expectations on strong sales of its blockbuster cancer drug Keytruda and HPV vaccine Gardasil. The pharmaceutical giant posted a quarterly loss, however, due to charges associated with the company’s acquisition of Prometheus Biosciences earlier this year. related investing news Merck swung to a net loss of $5.98 […]
Read More
Pfizer beats on earnings, but revenue misses as Covid product sales plummet
Pavlo Gonchar | Lightrocket | Getty Images Pfizer on Tuesday reported second-quarter adjusted earnings that topped Wall Street’s expectations, but posted revenue that fell short of estimates as Covid product sales plunged. Pfizer reported second-quarter sales of $12.73 billion, down 54% over the same period a year ago. Excluding sales of the company’s Covid vaccine […]
Read More
This little-known pharma stock can rally 50%, Citi says
It’s time to buy shares of Ionis Pharmaceuticals , according to Citi. The firm upgraded the stock on Monday to buy from neutral and raised its price target to $60 from $36. Citi’s new forecast now implies more than 50% upside from Friday’s close. The company is best known for its RNA-based therapeutics. Analyst David […]
Read More